Farmacologia y Toxicologia

  • ISSN: 2174-8365
  • Journal h-index: 1
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Mini Review - (2022) Volume 12, Issue 4

New Oncology Therapeutics: Cancer Drug Delivery with Targeted Delivery

Yakehira M* and Jacab Apelbeun
Jacab Apelbeun, Department of health and medicine, Sudan
*Correspondence: Yakehira M, Jacab Apelbeun, Department of health and medicine, Sudan, Email:

Received: 25-Jun-2022, Manuscript No. Ipft-22-116; Editor assigned: 27-Jun-2022, Pre QC No. Ipft-22-116 (PQ); Reviewed: 11-Jul-2022, QC No. QC No. Ipft-22-116; Revised: 18-Jul-2022, Manuscript No. Ipft-22-116(R); Published: 26-Jul-2022, DOI: 10.36648/2174- 8365.12.4.116


Increased patient adherence and pharmacological response to the therapy regimen have been observed as a result of advancements in medication formulations and novel drug delivery technologies during the past two decades. Efficiency and target-specific drug delivery or the degrees of distribution at any particular site of interest are two of the most challenging tasks. Many of the drug delivery systems that are now being developed are carefully crafted to maximise the delivery of a certain medication type while minimising drug degradation or loss. Targeted medication delivery is crucial when treating cancer because anticancer drugs cannot tell the difference between healthy and malignant cells, which can lead to side effects and/or systemic toxicity. In order to prevent side effects and promote medication accumulation at the targeted region, focused drug delivery is created; one such potential drug delivery method is magnetosome drug delivery, or drug delivery using magnetosomes (biological magnetic nanoparticles). In order to make the detection and treatment of cancer easier, we have outlined in this article the system for design, development, and mode of drug delivery using magnetosomes as well as current advancements in this area.

Alginate is an acidic, ocean colloid polysaccharide that is regarded as a biocompatible, nontoxic, non-immunogenic, and biodegradable biopolymer and polyelectrolyte. Numerous studies have supported the potential of alginate-based platforms as efficient drug delivery systems for cancer-targeted therapy. The development of delivery systems with cancer targets based on alginate is the main topic of discussion in this review. In particular, the basic chemical and physical characteristics of alginate are reviewed, along with several alginate-based delivery systems and alginate-based carriers. In order to emphasise research aimed at alginate optimization, current novel approaches to functionalize alginate-based vehicles for cancer targeting are highlighted.


Drug delivery systems; Cancer; Nanoparticles; Genetic engineering; Strategies and goals; Tumor; Therapeutics; Oncology


According to theory, normal cells undergo a change that gives rise to cancer cells. The inability to distinguish between healthy and diseased cells might lead to unwanted side effects and low therapeutic efficacy, given that anticancer medications are often harmful to both cancer and normal cells. It is critical to identify cancer cells from healthy cells with extreme precision in order to target and destroy cancer cells with pinpoint accuracy. It is important to select the right polymers while building these intelligent platforms. New medication delivery technologies and advancements in formulations have ushered in a new age over the past 20 years. The possibilities for comprehending the fundamentals of medication delivery and tissue-wide targeting have grown. Increased patient adherence and pharmacological response to the therapy regimen have been the results of these efforts. Efficiency and target-specific medication delivery or the degrees of distribution at any particular site of interest are two of the most challenging tasks. The majority of current drug delivery systems are specifically designed to increase the delivery of a specific drug by minimising drug loss or degradation, eliciting bioavailability, minimising side effects, and promoting and encouraging drug accumulation at the required bio zone (site) or other challenging issues related to therapeutic delivery targeting or physical stability of the drug [1, 2].

Cancer-related pain is a concerning issue that is accompanied by a variety of psychosocial reactions and a decreased quality of life. In advanced, metastatic, or terminal cancer, the prevalence of pain is 66.4%, and it is 55.0% when receiving anticancer treatment, according to a recent meta-analysis. Comparatively, a comprehensive analysis of pain in patients with head and neck cancer reported that 36% of patients still experienced pain six months after treatment and that 81% of patients experienced pain throughout cancer therapy. Additionally, it was frequently observed that post treatment pain was more intense than pretreatment discomfort. It seems that painful symptoms are frequently present with cancer in general and head and neck cancer in particular [3].

Some cancer patients require treatment beyond standard systemic analgesics due to intractable pain, systemic opioid tolerance, or adverse effects. This is due to the significant quantity of pain that cancer patients suffer. An established treatment for patients with untreated cancer-related pain, intrathecal administration of opioids has been linked to lower pain intensity scores and mean morphine equivalent doses. Typically, the catheter tip is positioned close to the area of pain that hurts the most, using the pain doctor's clinical judgement. Due to worries about intrathecal painkiller side effects in the cervical region close to vital structures of the body, patients with head and neck pain may find it challenging to receive the best placement. While TDD catheter tips are frequently positioned high in the cervical spinal canal in clinical practise, there is still a dearth of literature documenting this technique and its results. The literature on implanted intrathecal TDD for head and neck cancer pain focuses on catheter placement outside of the cervical region. Our study focuses on the effective application of an intrathecal TDD system catheter tip implanted at C1. An intrathecal catheter connected to an external infusion or an implantable pump may be used for intrathecal delivery of analgesics. Studies on intrathecal opiates have concentrated on external infusions given to hospice patients or cancer patients experiencing pain outside of their head and neck. The use of an implanted intrathecal TDD system to enhance the quality of life of a patient enduring cancer-directed treatment for head and neck cancer while maintaining hope for a cure is the main topic of our case report. In this case study, we describe a patient with recurrent metastatic oropharyngeal squamous cell carcinoma who had intrathecal TDD system implantation with catheter placement at the C1 level and experienced considerable reductions in daily oral morphine equivalents (OME) [4-6].

Materials and Methods

Materials used include hydroxypropyl methylcellulose (HPMC) (methocel K4M CR, surelease), ethylcellulose (EC aqueous dispersion) (sureteric) (Colorcon Limited, Kent, United Kingdom), and hydroxyethylcellulose (HEC) (degree of molar substitution = 2.5) (Merck, Darmstadt, Germany). All of these substances were purchased from Sigma Aldrich (Sigma Aldrich, MO, as excipients, lactose, sodium bicarbonate, microcrystalline cellulose (Avicel 101), and FMC Biopolymer's Avicel 101 (Saarchem, Krugersdorp, South Africa) were all used. The remaining reagents were all of analytical quality and were used exactly as they were bought [7- 10].


A crucial objective for the use of nanotechnology in tumour therapy is the delivery of payloads that are unique to different cell types. To target solid tumours, two strategies-active targeting and passive targeting-are frequently used. Due to the hyper vascular permeability and reduced lymphatic drainage of tumours, nanoparticles for passive targeting have a higher likelihood of extravasation from the vascular compartment into the tumour interstitium and decreasing the clearance of nanoparticles from the tumour interstitium. When a nanoparticle is actively targeted, its targeting moiety specifically detects the receptors expressed on the target cells and initiates receptor-mediated endocytosis. The nanoparticles then incorporate themselves into the desired cells. Multifunctional polymeric nanoparticles were created for MRI and intracellular drug release that targets tumours in the current investigation. The prostate cancer-specific aptamer Wy5a, which was created for the CRPC cell line PC-3 using the cell-SELEX approach in our earlier study, was added to the nanoparticle surface as a targeting moiety. In contrast to other cancer cells like DU145, 22RV-1, HeLa, and SMMC- 7721, Wy5a demonstrated a high level of selectivity for PC-3 cells. Our results revealed a substantial correlation between the intracellular delivery effectiveness of various formulations and their therapeutic efficacy. The intracellular transport of polymeric nanoparticles was made easier by the aptamer Wy5a. Therefore, both in vitro and in vivo, targeted polymeric nanoparticles could inhibit tumour growth more potently than non-targeted nanoparticles.

In our earlier investigation, a number of chemical procedures were used to create the targeted nanoparticle formulation, including the production of drug-encapsulated nanoparticles, surface functionalization, and conjugation of the targeting moiety. However, the multistep synthesis method, which produced systems that were fundamentally inefficient, was likely to cause changes from batch to batch and had a limited capacity for accurately engineering the NP surface, attributes. The pre functionalized biomaterials in this study were created prior to the formation of the appropriate nanoparticle components and contained all of the desired nanoparticle components. Additionally, using a straightforward purification technique and the pre functionalized biomaterials, the targeted nanoparticles were self-assembled in one step without the need for further post particle modification. To prevent the needless masking of Apt on the nanoparticle surface, which was tuned to be maximally targeted and stealthy, the amount of aptamer on the surface of nanoparticles could be changed by varying the ratios of PLGA-b- PEG-b-Wy5a with PLGA-b-PEG. Additionally, it is thought that the FDA-approved polymers PEG and PLGA, which are biocompatible, are well tolerated for prospective medicinal uses.

This study looked on MRI-visible polymeric nanoparticles that could be used for multifunctional imaging and treatment of tumours. Our findings suggested that multifunctional polymeric nanoparticles reserved SPION's saturation magnetization and super paramagnetic feature. Meanwhile, the SPION clustering inside the nanoparticle core led to a higher T2 relativity value when compared to Resovit, a commercially available product. Significant T2-contrast enhancement was seen by MRI as a result of the tumour cells' internalisation of SPIO-loaded polymeric nanoparticles [10].


It is generally recognised that the clinical applications of many anticancer medicines have been constrained by their flaws, including off-target effects, suboptimal bio distribution, and inadequate therapeutic efficacy. DDSs have been somewhat transformed by nanotechnology, microsphere methods, and other advancements in recent years, including cancertargeted drug delivery, with the main objective of increasing treatment efficiency and reducing adverse effects. Alginate is a naturally occurring polymer derived from the ocean that may be easily changed with specific groups or ligands to have cancer-targeting properties since it has a lot of free hydroxyl and carboxyl groups in the molecular chain. Various drugs now have the above-mentioned features, including decreased toxicity, higher bioavailability, and improved absorption, thanks to advancements in alginate-based technology. Combining alginate and its derivatives with several drug delivery systems has promise for accelerating the cancer treatment process and safeguarding encapsulated pharmaceuticals against deterioration. As a result, it is generally anticipated that the use of alginate in DDSs that target cancer will enhance the future prospects of the pharmaceutical and biotechnology businesses. Alginate-based platforms are incredibly promising carriers for effective medication delivery to cancer locations, as was previously discussed.

Conflicts of Interest





  1. Patra JK, Das G, Fraceto LF (2018) Nano based drug delivery systems: recent developments and future prospects. J Nano biotech 16:71.
  2. Indexed at, Google Scholar

  3. Edgar JYC, Wang H (2017) Introduction for design of nanoparticle-based drug delivery systems. Curr Pharma Design 23:2108-2112.
  4. Indexed at, Google Scholar, Crossref

  5. George A, Shah PA, Shrivastav PS (2019) Natural biodegradable polymers based nano-formulations for drug delivery: a review. Int J Pharmac 561:244-264.
  6. Indexed at, Google Scholar, Crossref

  7. Zimmer A, Kreuter J (1995) Microspheres and nanoparticles used in ocular delivery systems. Advanced Drug Delivery Reviews 16:61-73.
  8. Google Scholar, Crossref

  9. He S, Cheng X, Li Z, Shi X, Yang H et al (2016) Green and facile synthesis of sponge-reinforced silica aerogel and its pumping application for oil absorption. J Mater Sci 51:1292-1301.
  10. Google Scholar

  11. Lavoine N, Bergstrom L (2017) Nano cellulose-based foams and aerogels: processing, properties. and applications J Mate Chemistry 5:16105-16117.
  12. Google Scholar

  13. Gordon MS, Matei  D, Aghajanian C (2005) Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status. Journal of Clinical Oncology 23:16S.
  14. Indexed at, Google Scholar

  15. Gordon AN, N. Finkler, R. P. Edwards (2021) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicentre study.  Int J Gyne Cancer 15:785-792.
  16. Indexed at, Google Scholar

  17. J D Wright, A. Hagemann, J S Rader (2006) Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. Cancer 107:83-89.
  18. Google Scholar, Crossref

  19. A. A. Alvarez, H. R. Krigman, R. S. Whitaker, R. K. Dodge, and G. C. Rodriguez et al. (1999) The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clini Cancer Res 5:587-591.
  20. Indexed at, Google Scholar

Citation: Yakehira M, Apelbeun J (2022) New Oncology Therapeutics: Cancer Drug Delivery with Targeted Delivery. Farmacologiay Toxicologia, Vol. 12 No. 4: 116